← Leaderboards
Pierre Riviere
Peptide Logic, Llc
$9,134,558
Attributed
$9,238,021
Total exposure
10
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.4M · FY2016–22$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$9,238,021 · 10
By mechanism
R44$5,950,812 · 3
R43$3,287,209 · 7
Top collaborators
- Frank Porreca1 shared
Others in their field
Top investigators on “Programs”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,641,009,751
- Leonard Freedman · Leidos Biomedical Research, Inc.$994,984,644
- Lawrence Corey · Fred Hutchinson Cancer Center$730,186,538
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$609,313,548
Research focus
ProgramsDosePeptidesDesignSmall Business Innovation Research GrantPeripheralSuccessQuality Of LifeBasePainResponseFollow-UpOpioidAdverse EffectsHalf-LifeSubcutaneousClinical CandidateSafetyFemaleMaleMonoclonal AntibodiesAgonistIntravenousLead
Grant awards (14)
Peptide-antibody conjugate kappa-opioid receptor (PAC-KOR) agonists for treatment of chronic itch$499,449
R43 · FY2022 · NS · contact PI
Long acting and peripherally restricted kappa-opioid receptor agonists for acute migraine treatment$199,432
R43 · FY2022 · NS · contact PI
Prolactin monoclonal antibodies (PRL-mAbs) for the treatment of female-predominant pain syndromes$199,308
R43 · FY2022 · NS · contact PI
Long acting and peripherally restricted kappa-opioid receptor agonists for acute migraine treatment$499,290
R43 · FY2021 · NS · contact PI
Prolactin monoclonal antibodies (PRL-mAbs) for the treatment of female-predominant pain syndromes$496,611
R43 · FY2021 · NS · contact PI
Peripherally-Restricted Long-Acting Somatostatin Receptor 4 (LA-SSTR4) Agonists for Pain$1,410,027
R44 · FY2020 · NS · contact PI
Peripherally-Restricted Long-Acting Somatostatin Receptor 4 (LA-SSTR4) Agonists for Pain$1,585,395
R44 · FY2019 · DA · contact PI
Peripherally-restricted and long-acting kappa-opioid receptor (LA-KOR) agonists for pain$1,431,363
R44 · FY2019 · DA · contact PI
Peripherally-restricted and long-acting MAS1(LA-MAS1) agonists for pain$347,799
R43 · FY2019 · DA · contact PI
Peripherally-restricted and long-acting kappa-opioid receptor (LA-KOR) agonists for pain$1,524,027
R44 · FY2018 · DA · contact PI
PERIPHERALLY-RESTRICTED LONG-ACTING SOMATOSTATIN RECEPTOR TYPE 4 (LA-SSTR4) AGONISTS FOR PAIN$279,411
R43 · FY2018 · DA · contact PI
PERIPHERALLY-RESTRICTED LONG-ACTING SOMATOSTATIN RECEPTOR TYPE 4 (LA-SSTR4) AGONISTS FOR PAIN$260,861
R43 · FY2018 · DA · contact PI
Bi-Functional Peptides to Block Vasodilation and Vascular Leakage in Sepsis$298,121
R43 · FY2017 · GM · contact PI
Long-Acting Peripherally-Restricted Peptidic Kappa Opioid Receptor Agonists for Pain$206,927
R43 · FY2016 · DA · contact PI